Plain-English translation of NCT06280703 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new experimental insulin called to see how it works in the body and how well it controls blood sugar. Researchers will first test it in healthy volunteers, then in people with type 1 diabetes, comparing it to an existing long-acting insulin called . The goal is to understand whether this new treatment could be a better option for managing type 1 diabetes.
People with type 1 diabetes need insulin to survive, but current treatments require frequent injections or pump management. This medication is being developed to see if it could provide longer-lasting blood sugar control with potentially fewer injections, making diabetes management easier for patients.
You likely qualify if…
You likely don't qualify if…
The trial has four parts lasting 10–13 weeks each. Healthy volunteers receive one or two doses of the medication or placebo as an injection or IV infusion, with blood tests to see how the body processes it. People with type 1 diabetes receive either the new medication or an existing insulin, also given by injection or IV, with frequent blood tests and visits to measure blood sugar control and watch for side effects. Some participants may stay in a research facility for monitoring periods.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Germany